Company / Total Assets
VYNE Therapeutics Inc. Total Assets History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$66.9M
FY2025
5-year range
$40.8M / $97.7M
FY2021-FY2025
Trend
+0.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Total Assets has fluctuated over the past 8 years, ranging from $41M in FY2022 to $140M in FY2018.
Based on SEC 10-K filings.
$67M in FY2025 with a 5-year CAGR of -6.5%.
Declined from $98M to $67M over the past 2 years.
Total Assets over time
Growth rates
- 3-Year CAGR
- +18.0%
- 5-Year CAGR
- -6.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -6.5%, indicating a declining trend.
- In FY2025, total assets increased 0.0% year-over-year.
- Peak total assets was recorded in FY2018.
- Lowest total assets in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.19 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $66.9M | +0.0% |
| FY2024 | $66.9M | -31.5% |
| FY2023 | $97.7M | +139.7% |
| FY2022 | $40.8M | -39.2% |
| FY2021 | $67.0M | -28.5% |
| FY2020 | $93.7M | +18.4% |
| FY2019 | $79.2M | -43.4% |
| FY2018 | $139.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026